Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimta LabsBOM:524394 -2.41%85 PS Ratio is 6.81 as of Aug. 13, 2026, which is 149% above its 10-year median of 2.74. GuruFocus rates BOM:524394 with a GF Score™ of 85/100 and a GF Value™ of ₹508.27 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 200 Medical Diagnostics & Research companies, Vimta Labs ranks worse than 77% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Vimta Labs's share price is ₹632.45.
Vimta Labs's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹92.86. Hence, Vimta Labs's PS Ratio for today is 6.81.
The historical rank and industry rank for Vimta Labs's PS Ratio or its related term are showing as below:
BOM:524394'
s PS Ratio Range Over the Past 10 Years
Min: 0.71 Med: 2.74 Max: 10.75
Current: 6.75
During the past 13 years, Vimta Labs's highest PS Ratio was 10.75. The lowest was 0.71. And the median was 2.74.
BOM:524394's PS Ratio is ranked worse than 77% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.79
vs BOM:524394: 6.75
Vimta Labs Ltd has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Vimta Labs was 14.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 9.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 11.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 11.10% per year.
During the past 13 years, Vimta Labs's highest 3-Year average Revenue per Share Growth Rate was 20.10% per year. The lowest was 2.30% per year. And the median was 7.80% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Vimta Labs PS Ratio Related Terms
Vimta Labs PS Ratio Historical Data
* Premium members only.
The historical data trend for Vimta Labs's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Vimta Labs's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimta Labs PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimta Labs's PS Ratio distribution charts can be found below:
* The bar in red indicates where Vimta Labs's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Vimta Labs's Share Price of today is ₹632.45. Vimta Labs's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹92.86.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Vimta Labs (BOM:524394) has a PS Ratio of 6.81 as of Aug. 13, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Vimta Labs and its competitors. This is 149% above median its historical median of 2.74. Over the past decade, Vimta Labs' PS Ratio has ranged from 0.71 to 10.75. According to the industry distribution chart, Vimta Labs ranks #154 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 77%.
Is Vimta Labs' PS Ratio too high?
Vimta Labs' current PS Ratio of 6.81 is 149% above median its 10-year median of 2.74. Over the past 10 years, this metric has ranged from a low of 0.71 to a high of 10.75. The Medical Diagnostics & Research industry median PS Ratio is 2.79. Vimta Labs' value of 6.81 is 144.1% above this industry median. Based on the distribution chart, Vimta Labs ranks #154 out of 200 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Vimta Labs has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vimta Labs' PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimta Labs ranks #154 out of 200 companies for PS Ratio. This places Vimta Labs in the lower half of its industry. The industry median PS Ratio is 2.79. Vimta Labs' value of 6.81 is 144.1% above this benchmark. Historically, Vimta Labs' own PS Ratio has ranged from 0.71 to 10.75 over the past decade. While the company's 10-year median is 2.74 vs. the industry median of 2.79, Vimta Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.79, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimta Labs's current PS Ratio of 6.81 is 144.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Vimta Labs and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimta Labs's current PS Ratio is 6.81, which is 149% above median its own 10-year median of 2.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimta Labs stock overvalued right now?
Based on GuruFocus' analysis, Vimta Labs (BOM:524394) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹508.27, compared to a current price of ₹632.45 — trading 24.4% above its estimated fair value. The current PS Ratio is 6.81, which is 149% above median its 10-year median of 2.74 and 144.1% above the Medical Diagnostics & Research industry median of 2.79. Vimta Labs' overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Vimta Labs (BOM:524394), the current PS Ratio is 6.81 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimta Labs (BOM:524394) Overvalued in 2026?
Based on GuruFocus' analysis, Vimta Labs stock appears to be overvalued.
The current stock price of ₹632.45 is trading 24.4% above its estimated GF Value™ of ₹508.27.
GuruFocus considers Vimta Labs to be Modestly Overvalued.
Key valuation signals for BOM:524394:
PS Ratio: 6.81 (149% above median its 10-year median of 2.74)
GF Value™: ₹508.27 vs. price of ₹632.45 (24.4% above fair value)
Industry Position: 144.1% above the Medical Diagnostics & Research median (#154 of 200)
No single metric tells the full story. See the BOM:524394 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimta Labs Ltd is a comprehensive contract research and testing organization, providing a wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and many other industries. Its services portfolio includes testing and contract research services in the fields of clinical research, pre-clinical research, clinical diagnostics, biopharma services, analytical testing, research and environmental studies, and Others. It has only one reportable segment namely Contract Research and Testing Services which generates the revenue.
85GF Score
Get the complete analysis for BOM:524394
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524394 has been successfully added to your 
